Delving into the Latest Updates on QTP101 with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Tuberculosis

Inactive Indication-

Originator Organization

Quratis, Inc.Startup

Active Organization

Quratis, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Author: Tokoro, Akihiro ; Tanimukai, Hitoshi ; Kanemura, Seitetsu ; Tsujimoto, Hiroshi ; Tokuyama, Madoka ; Tsujio, Ichiro ; Matsuda, Yoshinobu ; Takei, Kiyozumi ; Nakajima, Shinichiro ; Maeda, Isseki ; Taira, Toshihiro ; Kashiwagi, Yujiro ; Okamoto, Yoshiaki ; Kai, Toshihiro ; Watanabe, Motoo ; Goya, Sho

To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS). The symptom severity was evaluated by the memorial delirium rating scale (MDAS) on days 0, 3, and 7 following intervention. Significant improvements in total MDAS scores were found in all groups on day 3. However, on day 7, only the short T1/2 group and MARTA group showed significant improvement. Consideration of an AP’s pharmacological properties may be helpful for improving the outcomes of pharmacological delirium intervention in patients with cancer.

100 Deals associated with QTP101

Login to view more data